LIVERFASt GP+(LIVERSTAT), a non-invasive blood testing for NAFLD staging improves risk stratification of patients with indeterminate FIB-4 results

Naim Alkhouri (1), Anita Kohli (1), Phillip Leff (1), Rida Nadeem (1), Mona Munteanu (2)

(1) Arizona Liver Health, Phoenix, AZ, USA. (2) Fibronostics Inc. US, Medical Affairs Department, Florida, US

INTRODUCTION

- **LIVERFASt GP+ (LIVERSTAT)** (Fibronostics, Florida, US), an AI-based proprietaryblood test, was validated against liver biopsy (LB) to identify the presumed NAFLD clinical stages. (Poster 431-SAT)
- GP+ variables are common blood biomarkers (lipid panel, liver enzymes, glucose and total bilirubin bilirubin) with patient's anthropometrics.

AIMS

The primary aim was to assess retrospectively the GP+ (LIVERSTAT) performance and concordance rate (CR) with liver biopsy and Fibroscan as second step after FIB-4 for the assessment of advanced fibrosis (F3F4) in NAFLD patients.

METHODS

N=176 NAFLD Patients with prospectively collected **GP+ (LIVERSTAT)** have been included from a tertiary hepatology center with biopsy- proven NAFLD and concomitant FIB-4 and liver stiffness measurement (LSM).
AUC(SE) and C-statistics were used to assess the accuracy of each noninvasive test (NIT) against liver biopsy

FIB-4 cut-offs to rule-in and rule-out advanced fibrosis F3F4

GP+ (LIVERSTAT) has been trained and validated against histopathological classification to identify the presumed AFLD clinical classes:

Class 0	No presumed fibrosis/steatosis
Class 1	Presumed steatosis only
Class 3	Presumed fibrosis, not advanced
Class 4	Presumed advanced fibrosis



RESULTS

CHARACTERISTICS OF INCLUDED PATIENTS

Epidemiological Characteristics	Prevalences , median (SE or range)
Male Gender	57.2%
Age	57.2 (0.8)yrs
Type 2Diabetes	47.4%
ALT	52 (3) U/L
BMI	37.7 (0.6) Kg/m2

NITs	AUCs for F3F4 stages (Prevalence 45%)
GP+	0.69(0.04),
FIB-4	0.76(0.04)
LSM by Fibroscan	0.76(0.04)
P values	NS



NITs	Concordance with Liver Biopsy		
	FIB-4 < 1.3	FIB-4 1.3 – 2.67	FIB-4 ≥ 2.68
G+\P+	71%	60%	68%
LSM	31%	28%	68%
FIB-4	17%	53%	58%



CONCLUSIONS

GP+ (LIVERSTAT), is readily available and can be used to identify F3-F4 as a second step in patients with indeterminate FIB-4.

REFERENCES

1. https://www.. fibronosticscom/
2. Sandulescu O, et al. Presumed NASH fibrosis as per non-invasive screening blood marker LIVERFASt-GP+ is predictive for Covid-19 short-term severe outcome. EASL NASH Summit. J Hepatol 2022
3. Quiambao R, et al. ., et alLIVERFASt GP+ (LiverSTAT), first-line screening tool in at-risk MAFLD paCents outperformed standard of-care (SOC) FIB-4
Ronald Quiambao (1), Imtiaz Alam (2), Paul Hermabessière (3), Adèle Delamarre(3), Juan-Manuel Munoz Perez (4),

CONTACT INFORMATION

nalkhouri@azliver.com

DISCLOSURES

MM - Fibronostics